Ferring acquires licensing rights for Albireo’s elobixibat for irritable bowel

Tuesday, July 3, 2012 11:06 AM

Swiss research-driven specialty biopharmaceutical group Ferring Pharmaceuticals and Swedish biotech Albireo have signed a license agreement under which Ferring has rights to develop and commercialize elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

The agreement gives Ferring rights to market elobixibat globally with the exception of Japan and a small number of Asian markets. In consideration of the rights, Ferring will pay Albireo a significant upfront undisclosed licensing fee, milestones and tiered double-digit royalties. Ferring will also be responsible for development costs in its territory.

The agreement is one of the biggest investments made by Ferring for licensing rights of a product. Ferring believes that the novel therapy elobixibat, which is targeting a currently under-served, but large patient population, will significantly strengthen its gastroenterology portfolio. Elobixibat is due to enter phase III trials for the CIC indication and phase IIB trials for the IBS-C indication shortly.

"Elobixibat perfectly complements our gastroenterology portfolio, which includes Pentasa for IBD and Picoprep for bowel cleansing. We also have several promising products in our pipeline within gastroenterology," said Michel Pettigrew, president of the executive board and COO at Ferring. "It fits well with our company philosophy of ‘People Come First’—in particular the patient, as it addresses a problem that affects from 15% up to almost a third of the population, but that has seen little progress in treatment options over the years."

Jan Mattsson, executive director of the board and COO of Albireo, added, "We are excited to enter into this agreement and look forward to collaborating with Ferring to bring this novel therapy to patients around the world suffering from CIC or IBS-C. Ferring has a long and strong track record in gastroenterology and we believe will be an ideal partner for Albireo and elobixibat in this territory."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs